Payment overview · 2025
General Payments
$2,421.27
136 reported records · 23 companies
Healthcare provider profile · identity verified
Kory R Guidry, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BAYTOWN, TX · NPI 1477533693
Verified facts
What the public records show
CMS Open Payments records show Kory R Guidry, M.D. received $2,421.27 in general payments during 2025 across 136 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 17.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Mounjaro, Ozempic, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 254 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $421.23 | 17.4% | 22 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $311.43 | 12.9% | 24 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $302.27 | 12.5% | 22 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $264.15 | 10.9% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $217.52 | 9.0% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $178.03 | 7.3% | 13 | 2025 |
| Avvisto Therapeutics, LLC | Unresolved — no canonical attribution shown | $135.19 | 5.6% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $81.41 | 3.4% | 4 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $68.30 | 2.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $63.25 | 2.6% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $52.70 | 2.2% | 2 | 2025 |
| Verity Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $41.19 | 1.7% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $36.57 | 1.5% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $33.91 | 1.4% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $32.17 | 1.3% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $30.58 | 1.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $29.66 | 1.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.40 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.22 | 1.2% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.58 | 0.7% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $16.25 | 0.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.72 | 0.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $14.54 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,421.27 | 136 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $421.23 | 22 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $311.43 | 24 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $311.43 | 24 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $248.00 | 18 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $247.06 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $230.25 | 17 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $182.22 | 10 | 2025 |
Source payment records
|
|||||
| CYCLOSET Normalized: cycloset |
Drug | Avvisto Therapeutics, LLC | $135.19 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $125.15 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $115.60 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $111.88 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $84.53 | 6 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $68.30 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $63.25 | 3 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $59.25 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $52.70 | 2 | 2025 |
Source payment records
|
|||||
| Tlando Normalized: tlando |
Drug | Verity Pharmaceuticals Inc. | $41.19 | 2 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $36.57 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $33.91 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $30.58 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $29.66 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $29.40 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.22 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $17.58 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $16.25 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $8.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 64 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 254 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 48 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
48 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
61 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
254 | 55 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 385 | 131 |
| Gabapentin | Gabapentin | 285 | 86 |
| Levothyroxine Sodium | Levothyroxine Sodium | 262 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 260 | 85 |
| Ozempic | Semaglutide | 254 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 223 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 206 | 56 |
| Metformin Hcl | Metformin Hcl | 195 | 58 |
| Trazodone Hcl | Trazodone Hcl | 193 | 53 |
| Lisinopril | Lisinopril | 192 | 60 |
| Sertraline Hcl | Sertraline Hcl | 181 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 174 | 48 |
| Furosemide | Furosemide | 166 | 51 |
| Tramadol Hcl | Tramadol Hcl | 159 | 46 |
| Montelukast Sodium | Montelukast Sodium | 156 | 51 |
| Alprazolam | Alprazolam | 155 | 28 |
| Losartan Potassium | Losartan Potassium | 145 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 140 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 137 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 38 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 124 | 28 |
| Clonazepam | Clonazepam | 117 | 25 |
| Ezetimibe | Ezetimibe | 117 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 116 | 22 |
| Methylprednisolone | Methylprednisolone | 111 | 84 |
| Lorazepam | Lorazepam | 110 | 27 |
| Diazepam | Diazepam | 109 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 100 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 35 |
| Cephalexin | Cephalexin | 96 | 69 |
| Allopurinol | Allopurinol | 94 | 28 |
| Eliquis | Apixaban | 87 | 22 |
| Glipizide | Glipizide | 87 | 31 |
| Potassium Chloride | Potassium Chloride | 87 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 30 |
| Simvastatin | Simvastatin | 84 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 80 | 29 |
| Finasteride | Finasteride | 80 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 30 |
| Nifedipine Er | Nifedipine | 77 | 22 |
| Prednisone | Prednisone | 77 | 61 |
| Carvedilol | Carvedilol | 76 | 28 |
| Omeprazole | Omeprazole | 75 | 24 |
| Pregabalin | Pregabalin | 75 | 20 |
| Temazepam | Temazepam | 73 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 70 | 26 |
| Glimepiride | Glimepiride | 65 | 19 |
| Donepezil Hcl | Donepezil Hcl | 64 | 20 |
| Jardiance | Empagliflozin | 64 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 18 |
| Levofloxacin | Levofloxacin | 58 | 50 |
| Azithromycin | Azithromycin | 56 | 47 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 54 | 34 |
| Meloxicam | Meloxicam | 51 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 14 |
| Synthroid | Levothyroxine Sodium | 48 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 14 |
| Amoxicillin | Amoxicillin | 42 | 34 |
| Liothyronine Sodium | Liothyronine Sodium | 41 | 12 |
| Gemfibrozil | Gemfibrozil | 40 | 14 |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 40 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | 13 |
| Propranolol Hcl | Propranolol Hcl | 39 | 11 |
| Repatha Sureclick | Evolocumab | 39 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 39 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 39 | suppressed |
| Fluconazole | Fluconazole | 37 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 20 |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Nabumetone | Nabumetone | 35 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 35 | 11 |
| Glipizide Er | Glipizide | 34 | suppressed |
| Nateglinide | Nateglinide | 34 | suppressed |
| Topiramate | Topiramate | 34 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | 12 |
| Clindamycin Hcl | Clindamycin Hcl | 31 | 24 |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 12 |
| Spironolactone | Spironolactone | 31 | 12 |
| Metformin Hcl Er | Metformin Hcl | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Celecoxib | Celecoxib | 28 | 13 |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Dapsone | Dapsone | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | 11 |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 16 |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Ssd | Silver Sulfadiazine | 19 | 12 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 19 | 14 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 14 |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Nystatin | Nystatin | 17 | suppressed |
| Tadalafil | Tadalafil | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Anastrozole | Anastrozole | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Modafinil | Modafinil | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Fondaparinux Sodium | Fondaparinux Sodium | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,421.27 · 136 records | Bayer Healthcare Pharmaceuticals Inc. | AREXVY, Auvelity, BREZTRI, CYCLOSET, Cologuard Collection Kit, Dyanavel XR, JARDIANCE, JATENZO, KISUNLA, Kerendia, LEQVIO, LINZESS, Leqembi, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, QULIPTA, Qelbree, REPATHA, REXULTI, Rybelsus, SYNTHROID, Sunosi, TRELEGY ELLIPTA, Tlando, UBRELVY, Veozah, XIFAXAN, XYOSTED, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error